The all-oral combination is supported by phase 3 LITESPARK-011 data showing improved progression-free survival compared with cabozantinib.
|Articles|February 15, 2021
Pharmacy Times: Week of February 15 Lineup
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.
Advertisement
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week, including:
- A video interview with Susan Swindells, MD, a professor in the Department of Internal Medicine and Medical Director in the Specialty Care Clinic at the University of Nebraska Medical Center, on a once-monthly, long-acting regimen for HIV recently approved by the FDA and how it will impact care for patients with HIV.
- A new episode of Pharmacy Focus that discusses performance measures in pharmacy and leadership techniques for pharmacists with Jesse McCullough.
- An article that provides an overview on the importance of sleep in infant children. Studies have shown that sleep benefits infants’ memories and general cognitive and emotional development.
Advertisement
Related to this article
The FDA approved lirafugratinib for adults with previously treated, advanced cholangiocarcinoma harboring an FGFR2 fusion or other rearrangement after the REFOCUS trial showed a 46% ORR.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly) is designed to deliver steady basal insulin levels over a full 7-day duration.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Long-term CASSIOPEIA Registry results show that daratumumab maintenance supports sustained minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Infection prevention during bispecific antibody treatment requires pharmacists to coordinate baseline screening, antimicrobial prophylaxis, immunoglobulin monitoring, vaccination, and rapid evaluation of suspected infections.
Advertisement
Advertisement
Trending on Pharmacy Times
1
After 180 Years, Multiple Myeloma Gets a Definition of Cure
2
Severe Asthma's Effects May Extend Beyond the Lungs, Brain Imaging Study Suggests
3
Alcohol and GLP-1 Therapy: Key Counseling Points for Pharmacists
4
FDA Approves Belzutifan Plus Lenvatinib for Advanced Renal Cell Carcinoma After Immunotherapy
5